Results from Cleveland Clinic's retrospective study indicate tofacitinib to be a safe and viable treatment option for patients with severe alopecia areata.
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Long Term Treatment for Severe Alopecia Areata with Oral Tofacitinib Citrate
1. Long-Term Treatment for Severe Alopecia
Areata with Oral Tofacitinib Citrate
Melissa Piliang, MD, FAAD
Dermatology and Pathology
Cleveland Clinic
Allergan
Incyte
Conflict of interest
Concert
Samumed
Allergan
P&G
Co-authors
Wilma Bergfeld, MD
Sara Hogan, MD
2. What’s New in Alopecia Areata
Killing two birds with one stone
Images obtained via Google, in public domain
25 year old man
Alopecia areata since childhood
Alopecia universalis for 7 years
Psoriasis
The case that stirred an interest in Jak I
4. OralTofactinib + AA: Cleveland Clinic Experience
2015-2018
• Retrospective, open-label
• 20 patients
• Mostly female (90%)
• More likely to have:
- Thyroid disease (65%)
- Atopy (40%)
- Many had autoimmune comorbitities
• RA, psoriasis
5. OralTofactinib + AA: Cleveland Clinic Experience
2015-2018
• Severe disease:
- Alopecia universalis - 70%
- Alopecia totalis - 20%
- Mean baseline SALT score - 88%
• Average length of current episode of
alopecia was 2.4 years
6. Doses ranged from 10-30 mg daily (most: 20 mg daily, divided dosing)
2017 analysis
Overall, majority of patients experienced some form of regrowth
47% had regrowth by 12 months
• Regrowth independent of
• age
• disease severity
• disease duration
• minimal side effect
JAMA Dermatol, 2017 Jun 153(6): 600-602
Oral Tofactinib + AA: Cleveland Clinic Experience
2015-2016
7. Long Term Use of Tofactinib for AA
Cleveland Clinic
2018 analysis
Baseline moderate to severe AA (n=20)
• Doses 10-30 mg daily
• 13/20 patients taking tofacitinib for over 12 months
• 30% with disease duration >20 years
• 12% with nail involvement
• 14/20 (70%) experienced hair regrowth by month 3
• 94% had regrowth by month 9 and 12
• SALT scores at month 3, 9, 12 months significantly lower than baseline
• 11/12 of patients on Tofa >12 months still with regrowth
• 3/12 (25%) with nail involvement had improvement
• Also noted by month 3
8. CC: Alopecia Universalis
HPI: 56 year old woman
• 23 year history of alopecia universalis
• Last notable hair growth was 19 years ago
• Previous Treatments
• Topical and intralesional corticosteroids
• Pimecrolimus
• Anthralin
• Diphenylcyclopropenone
• Methotrexate
• Numerous nutritional supplements
9. Past Medical History:
• Hashimoto’s thyroiditis on levothyroxine
• Hyperlipidemia
• Iron deficiency anemia
10. Physical Exam
• Complete loss of scalp hair,
eyelashes, eyebrows, body hair
- SALT score of 100
• Pitting and trachonychia of all
fingernails and toenails
11. Patient Course
Started
medication
5 mg BID
Nov 2015
First hair
growth
10 mg BID
Jan 2016
SALT 22
May 2016
Complete
regrowth
April 2017
Regrowth
maintained
November 2018
April 2016
Herpes
zoster
May 2018
Influenza A
SALT 100
12. Labs
CBC with differential
Peripheral eosinophilia (0.54)
May 2017: resolved (0.37)
December 2017: remains within normal limits (0.07)
CMP within normal limits
Lipid panel
Initiation, hypercholesterolemia: (Cholesterol 217, Triglyceride 147, LDL 143)
August 2016: hypertriglyceridemia (Cholesterol 250, Triglyceride 288, LDL 153)
September 2016: started on atorvastatin
September 2017: improved (Cholesterol 151, Triglyceride 178, LDL 68)
17. Mild Response
Cose: 10 mg BID (20 mg) – has been as high as 15 mg BID
Duration of therapy: 20 mo
Age: 53
Duration of disease: 10 yrs
Pre 18 Months10 Months
18. Minimal Response
Dose: 10 mg BID
Duration of therapy: 7 mo
Age: 61
Duration of disease: 5 yrs
Pre Post
19. No response
Dose: 10 mg BID
Duration of therapy: 7 mos
Age: 55
Duration of disease: 7 yrs
Pre Post
20. Current dose: 5 mg BID
Duration of therapy: 6 mos
Age: 53
Duration of disease: 30 yrs
Excellent response No response
Pre Month 6Month 5
21. What Happened?
Month 5
Month 6
1. She lost coverage -> off Jak I for several
weeks
2. Vit D was low
3. She was hypothyroid
-> levothyroxine dose change
22. Patien
t #
Se
x
Age at
treatment
initiation
Disease
duration
(years
since
diagnosis
of AA)
Time
since
last hair
growth
(years)
Months
until first
signs of
hair
growth
Duration
of
therapy
(months)
Holding
dose
(mg/day,
split
twice
daily)
SALT score
at
treatment
initiation
SALT
score at
final data
collection
Percent
regrowth
at time of
last
appointme
nt
1 F 50s 25 1 3 22 20 100 30.8 69%
2 F 40s 19 4 3 15 20 78.3 32.2 59%
3 F 20s 16 3 17 15 100 50.6 49%
4 F 50s 26 4 7 28 15 100 44.8 50%
5 F 30s 13 1 0 0.5 10 95 44 50%
6 F 50s 16 2 10 26 20 100 95 5%
7 F 60s 7 1 3 7 20 100 95 5%
8 F 40s 36 3 3 3 10 79.3 44.2 40%
9 F 50s 15 1 12 20 76 3 96%
10 F 30s 9 3 4 15 10 100 98 2%
11 F 50s 9 7 8 24 20 100 20 80%
12 F 50s 31 1 3 6 10 100 1 99%
13 F 50s 1 6 20 10 95 0 100%
14 F 30s 7 1 1 12 20 50 0 100%
15 F 50s 11 1 2 25 25 71.6 38 47%
16 M 20s 5
2
3 4 10 100
100 0%
“scant”
17 M 50s 3 2 2 12 20 100 50 50%
18 F 50s 16 6 2 5 10 90 47.2 48%
19 F 40s 17 8 13 10 50 0 100%
20 F 60s 44 1 3 4 10 100 100 10%
26. • 15 months
• 15 mg bid
• PsO/PsA flared
• No change or
disruption in dose
• No obvious reason
27. Durability with Long-Term Tofacitinib for AA
• 6 patients experienced medication interruption
• Adverse effect, illness, lapse in insurance coverage
• 4/6 (66%) with medication interruption
experienced shedding
• Noted within 4 weeks
• Resuming Tofacitinib after interruption had
stabilization of shedding within 1-2 months
• 2/20 discontinued due to adverse reactions
28. Tolerability with Long-Term Tofacitinib for AA
• LFT elevation (2/20) 10%
• Resolved with dose adjustment in 1, the other had to stop
tofa
• Hypercholesterolemia (3/20) 15%
• Noted by month 4 of treatment
• Slower to respond with dose adjustment
• Other:
• Lower Extremity Edema (1/20) 5%: medication
discontinued
• Palpitations (1/20) 5%: found to be hyperthyroid
• Leukopenia (1/20) 5%: transient
• Herpes reactivation (1/20) 5%
Safe but close monitoring (every 3-4 months) important
29. Summary Tofacitinib Long Term Data
• Results:
- 75% achieved some regrowth
- 60% - SALT50
- 25% - SALT90 (essentially fully regrowth)
- 30-40% - insufficient or no response
• Poor responders
- Increase to 15-20 mg daily
• Less likely to respond:
- Longer duration of episode (>10 years)
• Durability – 2 months post discontinuation –
shedding
30. Take Home Points
• This is a very exciting time for alopecia areata!
The era of biologic treatment of AA is just beginning
- Future
• More options- precision targeted therapy
• Better
• Safer
• More affordable (hopefully)
Support National Alopecia Areata Foundation (NAAF)
Thank you!